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Abstract
Background: To update and refine systematic literature review on the association between outpatient statins use and
mortality in patients with infectious disease.
Materials and Methods: We searched articles published before September 31, 2012, on the association between statins and
infectious disease-related mortality through electronic databases. Eligible articles were analyzed in Review Manager 5.1. We
conducted stratification analysis by study design, infection types, clinical outcomes and study locations.
Results: The pooled odds ratio (OR) for death (statins use vs. no use) across the 41 included studies was 0.71 (95%
confidence interval: 0.64, 0.78). The corresponding pooled ORs were 0.58 (0.38, 0.90), 0.66 (0.57, 0.75), 0.71 (0.57, 0.89) and
0.83 (0.67, 1.04) for the case-control study, retrospective cohort studies, prospective cohort studies and RCTs; 0.40 (0.20,
0.78), 0.61 (0.41, 0.90), 0.69 (0.62, 0.78) and 0.86 (0.68, 1.09) for bacteremia, sepsis, pneumonia and other infections; 0.62
(0.534, 0.72), 0.68 (0.53, 0.89), 0.71 (0.61, 0.83) and 0.86 (0.70, 1.07) for 30-day, 90-day, in-hospital and long-term (.1 year)
mortality, respectively.
Conclusions: Outpatient statins use is associated with a lower risk of death in patients with infectious disease in
observational studies, but in a less extent in clinical trials. This association also varies considerably by infection types and
clinical outcomes.
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Introduction
Severe infections always remain a major cause of morbidity,
mortality, and economic burden worldwide. For example, there
are nearly 751,000 cases of sepsis in the United States each year
and the number of cases is still increasing by 1.5% per year,
resulting in an annual estimated cost of $16.7 billions [1]. Despite
new advances in antimicrobial therapy and medical management,
only 50%–70% patients can survive from sepsis [2]. In addition,
Pneumonia induced by influenza and chronic obstructive pulmo-
nary disease (COPD) had caused thousands of deaths in several
epidemics [3], such as 1918 influenza epidemic, Asia influenza
during 1957–1958, Hong Kong influenza in 1968, and Spanish
influenza in 1942.
Statins, as one of the inhibitors of 3-hydroxy-3-methylglutaryl
coenzyme A reductase (HMG-CoA), are traditionally used to
lower the level of blood cholesterol in patients with cardiovascular
diseases or to prevent cardiovascular events. Recently, statins have
been proposed as novel therapeutic and preventive agents for
infection, given the increasing evidence, mostly from observational
studies, that statins are associated with a lower mortality in patients
with infectious disease [4–7]. Researchers believe that statins can
mitigate the inflammatory response in patients with sepsis or
COPD, which reflects its anti-inflammatory and immunoregula-
tion effects [8]. This may occur through several possible biological
mechanisms. Firstly, statins block the mevalonate pathway by
inhibiting HMG-CoA reductase, which interfere with the recog-
nition of microbial products by immune cell. They can also
decrease production of proinflammatory cytokines such as tumor
necrosis factor a (TNF-a), interleukin1 (IL-1), and IL-6 present
during sepsis and COPD, and thus depress the inflammatory
cascade [9]. Secondly, the antioxidant and anti-apoptotic proper-
ties of statins blunt the effects of sepsis [10]. Thirdly, the
antithrombotic properties of statins decrease the effect of sepsis-
induced coagulopathy [11]. Finally, statins increase the physiologic
concentrations of nitric oxide (NO) by increasing the expression of
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synthase, and thus reverse the endothelial dysfunction in sepsis
[12].These pleiotropic effects of statins have been demonstrated in
experimental models (in vitro and in vivo), and some [13–15] but
not all studies [4,6,7,16,17] showed serendipitous benefits of statins
to patients with severe infections, such as sepsis and COPD.
However, it is unclear which of them can explain the association
between statins and lower infectious disease-related mortality
observed in clinical observational studies.
So far, there are 4 published systematic reviews (3 of them are
quantitative analyses) on the studies on the association between
statins and infectious disease-related mortality [18–21]. Tleyjeh
et al. [18] reviewed 9 cohort studies published as of 2007 that
examined the effect of statins on infection-related mortality by
bacteremia (n=3), pneumonia (n=3), sepsis (n=2), and bacterial
infection (n=1). The pooled effect estimate (odds ratio or hazard
ratio of mortality) was 0.55 (95% CI, 0.36–0.83) in favor of statins.
Kopterides et al. [19] reviewed 15 studies published as of 2008
that examined statins and infection-related mortality: 10 of them
reported protective effects of statins, 4 showed null effects, and 1
showed risk/adverse effects. Janda et al. [20] reviewed 20 studies
on severe infections and sepsis published as of 2009. Among them,
15 studiesreported protective effects of statins [4,7,13–15,22–31]: 7
ones on 30-day mortality (OR, 0.61 [95% confidence interval or
CI, 0.48–0.73]), 7 ones on in-hospital mortality (OR, 0.38 [95%
CI, 0.13–0.64]). Bjorkhem et al. [21] reviewed 15 observational
studies comprising 113 910 patients between 2001 and 2009, and
found statin use was associated with a significantly (P,0.0001)
reduced mortality in patients suffering from bacterial infections
(OR, 0.52 [95% CI, 0.42–0.66]) but no longer significant after
adjusting for publication bias by precision estimate test (OR, 0.79,
[5% CI, 0.58–1.07]). However, these systematic reviews have not
sufficiently addressed the 3 critical challenges in this field: potential
time-varying effects of statins, the differential effects of statins by
types of infections, conflicting by results in different study design.
Answers to these 3 questions have important implications: they
can help us to better interpret (e.g. causality) on the observed
associations, and can also influence how physicians, patients, and
public health policy makers use the existing evidence. Moreover,
only 1 randomized clinical trial (RCT) was included in previous
reviews. Given the high validity of RCTs, it is important to include
more recently published RCTs into the review/meta-analysis to
provide a more conclusive interpretation on the potential effects of
statins on infectious disease-related mortality.
Therefore, this meta-analysis aimed 1) to update the literature
as of September 2012; 2) to summarize the association between
outpatient statins use and infectious disease-related mortality
across all published studies (observational studies and RCTs); 3) to
examine whether this association differ by study design, infection
types, outcome measures and study locations.
Methods
The systematic review and meta-analysis was performed
according to the recently published recommendations and
checklist of the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement.
Search Strategy
All searches were limited to ‘‘English language’’ and ‘‘humans’’.
Two researhers conducted literature search independently in 4
steps. Step 1, we searched abstracts of published articles in English
language through Pubmed, Ovid MEDLINE, and Ovid EMBASE
databases, using the following key terms: (statin OR statins OR
mevastatin OR simvastatin OR lovastatin OR fluvastatin OR
rosuvastatin OR cerivastatin OR pravastatin OR atorvastatin OR
hydroxymethylglutaryl-CoA Reductase Inhibitors) AND (infection
OR sepsis OR bacteremia OR pneumonia OR virus infectious
diseases OR respiratory tract infections OR organ transplantation
OR). The final date of literature search was September 31 2012.
Step 2, we excluded reviews, letter, comments, editorials,
corrected publications, duplicate publications and abstracts only.
Step 3, we screened all the remaining abstracts and selected those
that met our eligibility criteria (see exclusion criteria below). Step
4, we searched the full-text articles of these eligible abstracts.
Study Selection
Our included surveillance studies, cohort studies, case-control
studies, and RCTs that focused on statins and infectious diseases.
Infectious diseases in this Meta-analysis included phenomena,
COPD, sepsis, bacteremia, respiratory infection, organ transplan-
tation or any open surgery induced infection. Outpatient statins
use was defined as use of statins before the admission or both
before and during the hospitalization. We excluded studies that, 1)
only focused on the preventive effects of statins on the incidence of
infectious disease; 2) only had information on statins use during the
hospitation for observational study; 3) did not provide clear
definition of statins use; 4)had no outcome measures for infection-
related mortality.
Data Extraction and Quality Assessment
Two researchers (Ma Y and Peng J) independently reviewed the
included studies and used the same Excel spreadsheet to extract
relevant information of each study, including study objective,
sample demographics (i.e. age, gender), comorbidities, type of
infection, timing and dose of statins use, use of other medications
or treatments, outcome measures (30-day, 90-day, in hospital and
long-term mortality), association scale (OR or HR), and adjusted
confounders. Disagreement between the 2 reviewers was first
resolved by consensus. If consensus could not be reached, a senior
reviewer (Guo Z) was consulted for the final decision. For
observational studies, we used Newcastle-Ottawa Quality Assess-
ment Scale (NOS) [32] to assess their quality. NOS has 8 questions
reflecting 3 domains: quality of subject selection, comparability
between two groups, and reliability of exposure or clinical
outcomes. The full score of NOS is 9, and a score 8–9 is rated
as excellent, 6–7 as good, 5 or below as fair. For clinical trials, we
used Jadad Score [33] with 3 questions to assess the quality of
randomization, blinding, and withdrawals or dropouts The full
Jadad Score is 5, with 3–5 being rated as high quality and 1 or 2 as
low quality.
Statistical Analysis
We conducted quantitative data analyses in Review Manager
5.1 (StataCorp, College Station, Tex). We used I
2 statistic to test
heterogeneity across the included studies. An I
2 value of 0%
indicates absence of heterogeneity, while 25%, 50%, and 75%
indicates low, moderate, and high heterogeneity, respectively [34].
Random effects model was used for high level of heterogeneity and
fix effects model was used for low and moderate levels of
heterogeneity. We estimated pooled odds ratio (OR) and the
corresponding 95% confidence interval (CI) across studies by
weighting the Odds ratios of each individual study according to
their log-transformed inverse variance. We also conducted
subgroup analyses by study design, infection types, outcome
measures (30-day, 90-day, in-hospital mortality and long-term
mortality), and study locations (grouped by continents). Whenever
possible, we used the adjusted OR instead of the crude OR to
Statins on Infectious Disease-Related Mortality
PLOS ONE | www.plosone.org 2 December 2012 | Volume 7 | Issue 12 | e51548calculate pooled ORs. We conducted sensitivity analysis with fail-
safe number (Nfs) to calculate the number of negative studies
needed to get opposite association between statins and mortality in
patient with infectious disease. We also excluded single study or
groups of studies based on the study design, outcomes, and quality
score; re-ran the analysis to get new pooled ORs; and then
compared the new pooled ORs with the original OR for all
studies. This comparison can help to evaluate the appropriateness
Figure 1. Flowchart of included studies and selection progress.
doi:10.1371/journal.pone.0051548.g001
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included studies. We assessed potential publication bias with Egger
precision weighted linear regression tests and funnel plots [35].
Results
We identified 1499 potential eligible articles at the initial search.
Among them, there are 41 ones [2,4–7,13–17,22–30,36–57] met our
inclusion and exclusion criteria (Figure 1), including 1 surveillance
study, 2 case-control study, 19 respective cohort studies, 9 prospective
cohort studies and 10 RCTs. Stratified by types of infection, 16 focused
on pneumonia [4,7,14,16,17,22,25,27,29,37,38,51–54,56], 6 on bac-
teremia [5,6,15,26,36,45], 7 on sepsis [2,13,23,30,40,44,50], and 12 on
other infection [24,28,39,41–43,46–49,55,57]. Stratified by study
locations, 20 studies were conducted in North America, 16 in Europe,
1 in Oceania, 2 in Asia, and 2 others cross continents. The average age
of patients in these studies ranged from 40 to 75 years (Table 1).
According to NOS, the 30 included observational studies were
rated as excellent or good quality (score range, 7–9; mean, 8.15)
(Table 2). According to Jadad scale, the 10 included clinical trials
were rated as high quality (score range, 4–5; mean, 4.7), which
represented good quality of these studies.
The OR for death (statins use vs. no use) reported in the
included studies ranged from 0.06 to 1.50 (Table 2). Twenty three
studies found a protective effect of statins against death from
infection, but the other 18 studies found null effects. There was
substantial heterogeneity across the 41 studies (I
2 value, 74%),
which supported the use of random effect model for meta-analysis.
The overall pooled OR was 0.71 (95% CI: 0.64, 0.78) (Figure 2).
Table 3 shows the subgroup-specific pooled ORs and their 95%
CIs. Stratified by study design, the 10 RCTs showed null effect of
statins (pooled OR, 0.83 [0.67, 1.04]), whereas the observational
studies found beneficial effects: the subgroup-specific pooled ORs
were 0.58 (0.38, 0.90) for the case-control study, 0.66 (0.57, 0.75)
for retrospective cohort studies, and 0.71 (0.57, 0.89) for
prospective cohort studies, respectively (Table 3). Stratified by
types of infection, the protective effect of statins in bacteremia
patients was stronger than other types of infections: the subgroup-
specific pooled ORs were 0.40 (0.20, 0.78) for bacteremia, 0.61
(0.41, 0.90) for sepsis, 0.69 (0.62, 0.78) for pneumonia, and 0.86
(0.68, 1.09) for other infections, respectively (Figure 2). Stratified
by types of outcome, the subgroup-specific pooled ORs were 0.62
(0.54, 0.72) for 30-day mortality, 0.68 (0.53, 0.89) for 90-day
mortality, 0.71(0.61, 0.83)for in-hospital mortality and 0.86 (0.70,
1.07) for long-term mortality, respectively (Figure S1, S2, S3, S4,
S5). Stratified by the quality of individual study, the pooled OR
were 0.67 (0.59, 0.75) for observational studies rated as 8–9 score
and 0.36 (0.18, 0.70) for studies rated as 7 score. Stratified by study
locations, the pooled OR were 0.74 (0.65, 0.84) for studies in
North America, 0.66 (0.57, 0.77) for studies in Europe, 0.06
(95%CI: 0.01, 0.47) for the study in Oceania, and 0.76 (95%CI:
0.38, 1.53) for studies in Asia, 0.93 (0.59, 1.46) for studies cross
continents (Table 3).
There was substantial degree of heterogeneity across the
included 41 studies (I
2 statistic, 74%). The I
2 statistic did not
change considerably in the subgroup analyses based on total
quality score, or subcategories of the quality score, i.e. exposure
definition, outcomes, and confounding assessment. But the I
2
statistic was as low as 41% and 55%for clinical trials and studies in
Europe, respectively. In our sensitivity analysis, there was no
significant change in pooled OR when excluding any of the studies
(data not shown) or any group of studies by infection type. Another
sensitivity analysis showed that 938 negative studies were needed
for getting the opposite association between statins and mortality
in patient with infectious disease (Nfs=938) and tolerance level
was 103. Our Egger precision weighted linear regression tests
showed the existence of publication bias (P-value ,0.0001).
Funnel plot also showed the absence of small studies in which
statins mightincrease infectious disease-related mortality (Figure 3).
Discussion
In this meta-analysis, we systematically reviewed 41 studies
published during 2001–2012 on the association between statins use
and infectious disease-related mortality. Overall, most observa-
tional studies found that statins were associated with lower
mortality from infectious disease. Our pooled OR among these
observational studies was similar to those in 3 previous meta-
analyses by Tleyheh et al. [18], Surinder Janda et al. [20] and
Bjorkhem et al [21]. However, we did not find conclusive evidence
on this beneficial effect in clinical trials. In subgroup analysis,
statins use was associated with lower 30-day, 90-day, and in-
hospital mortality, but not with long-term mortality. Statins use
was associated with lower mortality from bacteremia, pneumonia,
and sepsis, but not with mortality from other infections and
intensive care unit (ICU) patients.
We found that the magnitude of the association between statins
use and infectious disease-related mortality tended to decrease
with time, i.e. strongest for 30-day mortality followed by 90-day
mortality and in-hospital mortality, and null for long-term
mortality. This time trend suggests that the beneficial effect (if
exists) of statins to lower infectious-disease related mortality may
be short-term only. However, this time trend should be interpreted
with caution due to potential misclassification of death outcome
based on medical records, especially for in-hospital mortality. The
substantial variation in hospitalization length posed a big challenge
on estimating and interpreting pooled effect size of statins use,
which can be confirmed by heterogeneity test within hospitaliza-
tion period subgroup (I
2 is 78%, P,0.0001).
We also found the magnitude of the association between statins
use and mortality was strongest in patients with bacteremia. This
suggests that the protective effect of statins may be superior for
bacteremia than other types of infection. Alternatively, this may be
partially explained by less use of antibiotics in patients with
bacteremia: only 1 out of 6 studies on bacteremia patients,
reported antibiotics use before the admission to hospital or during
hospital, compared with most studies among patients with other
types of infections (such as 100% in Kwong study and 20% in
Yende study).
In this analysis, we found the reported effects of statins use
varied strikingly by study design. Observational studies consistent-
ly supported the beneficial effect of statins in lowering infection
disease mortality, while all RCTs showed null effects. Though
RCTs often provide more valid results, these 10 RCTs can not
completely outweigh the evidence on the beneficial effect of statins
from observational studies. These ‘‘null-effect’’ RCTs are often
criticized for small sample size [58]. These criticisms usually are
based on two factors. Firstly, the formal sample size calculations
that compute the numbers of patients required prospectively, as if
the trial had not yet been carried out. Secondly, the true power
calculated when trial is over. Based on alpha level, sample size and
actual rates of primary events among control and experimental
patients, we did post-hoc analysis by re-calculating the power of 8
negative trials in 10 RCTs and found that only one trial’s
retrospective power is bigger than 80% (Serrugs 81.5%), and all
other 7 ones had power smaller than 80% (Fellstrom 8.9%,
Kjekshus 25.5%, Wanner 14.3%, Stegmayr 47.3%, Holdaas
70.9%, Makris 60.5%). This under-power might be caused by the
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PLOS ONE | www.plosone.org 10 December 2012 | Volume 7 | Issue 12 | e51548over-estimated event rate in control group and/or risk reduction
level. In these 7 trials, investigator assumed the statins may reduce
the risk of primary outcome by 20% to 50%, but the truth is the
observed related risk reduction is obviously lower than 20% except
for Makris study. This result indicated that the evidence to make a
negative conclusion of statins is not sufficient and suggested
retrospective sample size calculation is needed so as to add more
representative patients in the trial. The sample size recalculation
also showed that we still need 3–10 times of current number in
each RCT to get positive result. Beside that, almost all these RCTs
enrolled the patients who had existing cardiovascular disease. This
could lead to misclassification of infection-related death, because
of the difference between the primary and secondary infection. In
addition, infection-related mortality is not a primary outcome in
these studies on cardiovascular outcomes, and thus might not be
measured accurately or appropriately.
Unexpectedly, we did not find significantly protective effect of
statins against infection-related death in the 9 studies that focused
on severe patient or patients admitted to ICU
[7,23,26,28,36,39,40,51,57] respectively in bacterenia (0.38,
0.15–1.01), in sepsis (0.65, 0.29–1.44), in pneumonia (0.95,
0.84–1.07), but not in other infections subgroup (0.64, 0.44–
0.92). One explanation can be that those severe patients usually
have many severe complications [26,39]. These complications
often lead to adverse outcome and significantly increase the risk of
death, which may dim the moderate protective effects of statins.
Most interested us is that the result from only one clinical trial in
these 9 studies provided evidence supporting that statins might
affect the course of critically ill patients and decrees the ICU
mortality [57]. Considering the differences in study design and
implement between the observational studies and clinical trials, the
most probable reason for this opposite result is the opportune
moment of using statins. Patients in the observational studies
might have already been using statins to treat high cholesterol
(prevalent users). In clinical trials, however, statins were random-
ized to two groups after patients being recruited (new users).
Another reason is the time difference between the progresses of
critically ill and the onset time of statins. The immunomodulatory
effects of statins can occur within 24 hours and thus acute
treatment may down-regulate the level of pro-inflammatory
cytokines [59]. That is why the acute curative effect in clinical
trial is better than long-term effect in observational studies. These
findings suggest that long-term use of statins may not be able to
protect severe ICU patients against death from infection as
common or less severe patients. However, we need more evidence
from RCTs to confirm the acute effect of statin in reducing the
ICU mortality among ICU patient.
The moderate heterogeneity across the included 41 studies may
come from 2 main sources: study population and methodology.
The significantly lower I
2 statistics in Europe studies than that in
studies from other continents revealed the substantial difference in
study population (e.g. ethnics and study locations), especially for
limited source from Asia and Oceania population. For method-
ology, the low I
2 statistics in clinical trails indicated better quality
control and more reliable results than observational studies. Other
methodological heterogeneity included type of patients, type of
infection, and dose of statins use across different studies.
Study Strengths
This meta-analysis had several strengths. First, we included
much more RCTs than previous reviews (8 vs. 0 in Tleyjeh et al.’s,
0 in Kopterides’, 0 in Bjorkhem and 1 in Janda et al.’s). Inclusion
of these RCTs can substantially improve the validity of our
analysis. Secondly, we conducted subgroup analyses by 4
important factors, i.e. study design, types of infections, outcome
measures, and study locations. These subgroups analyses can help
us to better assess the sources of variation or inconsistency of
findings, and also better understand the specific subgroups of
patients that may benefit more or less from statins. Thirdly, we
assessed the quality of each study by well-established score scales
(NOS and Jadad Score). The relatively high quality of most
included studies can improve our interpretation of the pooled
effect estimates for stains use.
Study Limitations
Several limitations of this meta-analysis needed to be men-
tioned. First, we only included electronic database and published
articles. Both Egger’s test and asymmetry of funnel plotpotential
suggested the existence of publication bias. Second, this meta-
Figure 2. Forest plot of the association between statins and mortality for patients with infectious disease, by types of infection.
Note: Each comparison was presented by the name of the first author and the year of the publication. The studies were shown by a point estimate of
the OR and the accompanying 95% CI which were displayed on a logarithmic scale using a random effects model. The studies are sorted according to
the estimate of OR. Between-study heterogeneity was tested by the x
2 -based Q-statistic, and its impact was quantified by I
2 which can range
between 0 and 100%.
doi:10.1371/journal.pone.0051548.g002
Table 3. Subgroup analyses by study design, types of
infection, outcome measures and study location.
n
Pooled
OR 95% CI
Heterogeneity
(I
2)
Study design
Surveillance 1 0.59 (0.38–1.33) –
Retrospective cohort study 19 0.66 (0.57, 0.75) 82%
Prospective cohort study 9 0.71 (0.57, 0.89) 53%
Case-control study 2 0.58 (0. 38, 0.90) 0%
Clinical trial 10 0.83 (0.67, 1.04) 41%
Type of infection
Bacteremia 6 0.40 (0.20, 0.78) 77%
Sepsis 7 0.61 (0.41, 0.90) 55%
Pneumonia 16 0.69 (0.62, 0.78) 75%
Other infection 12 0.86 (0.68, 1.09) 52%
Outcome measure
30-day mortality 15 0.62 (0.54, 0.72) 77%
90-day mortality 5 0.68 (0.53, 0.89) 75%
In-hospital mortality 18 0.71 (0.61, 0.83) 78%
Long-term mortality 9 0.86 (0.70, 1.07) 39%
Study location
North America 20 0.74 (0.65, 0.84) 78%
Europe 16 0.66 (0.57, 0.77) 55%
Australia 1 0.06 (0.01, 0.47) –
Asia 2 0.76 (0.38, 1.53) 30%
Cross continents 2 0.93 (0.59, 1.46) 0%
doi:10.1371/journal.pone.0051548.t003
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trials (n=10). We did not assign different weighting to included
studies based on the validity of their study design (RCT vs.
observational studies). Third, 6 of the 10 included RCTs were
designed to test the effect of statins on cardiac outcomes rather
than infectious disease-related mortality. So the validity of
estimated associations from these RCTs may be comprised.
Fortunately, several ongoing clinical trials [60–63] (ID:
NCT00528580, NCT00979121, NCT00702130, NCT00676897,
http://www.clinicaltrials.gov) aim to specifically examine the
potential clinical benefit of statins in sepsis. We expect these
studies will yield more conclusive evidence on this important topic
in near future.
Conclusion
Based on this meta-analysis, we conclude that statins are associated
with a lower risk of death in patients with infectious diseases in
observational studies, but less in clinical trials. This beneficial effect
tends to be short-term only. It seems to be stronger in patients with
bacteremia but less for ICU patients with severe infection. More
worldwide clinical trials specifically on this topic are urgently needed to
provide more conclusive guideline for clinical practice.
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